awmsg logo



iloprost trometamol (Ventavis®)


Reference No. 163

Publication date:
13/03/2007


Appraisal information

iloprost trometamol (Ventavis®) 10 micrograms/ml nebuliser solution


Company: Bayer Healthcare Pharmaceuticals
BNF category: Cardiovascular system
NMG meeting date: Not scheduled
AWMSG meeting date: 05/12/2006
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: Not available
Ministerial ratification: 13/03/2007

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG recommends that iloprost trometamol (Ventavis®) should be made available for use within NHS Wales with the following restrictions: It is used according to its licensed indications within NHS Wales for the treatment of patients with New York Heart Association Class III primary pulmonary hypertension as a second-line treatment when oral treatments are ineffective or not tolerated. Iloprost trometamol (Ventavis®) should also be restricted for use only as an alternative in patients receiving other forms of prostacyclin treatment. Iloprost trometamol (Ventavis®) should be initiated by specialists in centres treating pulmonary hypertension.
Final Appraisal Recommendation (FAR)
Download